1 Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004;363(9426):2063–72.
2 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Behandlungsleitlinie Schizophrenie. Steinkopff, Darmstadt, 2006.
3 National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults. National Institue for Health and Care Excellence, London (GB), 2014.
4 National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and yound people. National Institue for Health and Care Excellence, London (GB), 2013.
5 Hasan A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44.
6 Hasan A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–78.
7 Buchanan RW, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93.
8 Dixon LB, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):48–70.
9 Drake RE, Whitley R. Recovery and severe mental illness: description and analysis. Can J Psychiatry. 2014;59(5):236–42.
10 Cavelti M, Kvrgic S, Beck EM, Kossowsky J, Vauth R. Assessing recovery from schizophrenia as an individual process. A review of self-report instruments. Eur Psychiatry. 2012;27(1):19–32.
11 Weltgesundheitsorganisation, Dilling H, Freyberger HJ. Taschenführer zur ICD-10-Klassfikation psychischer Störungen. 4. Auflage ed. 2008.
12 Mueser KT, Deavers F, Penn DL, Cassisi JE. Psychosocial treatments for schizophrenia. Annu Rev Clin Psychol. 2013;9465–97.
13 Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140(1-3):159–68.
14 Mizuno Y, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385–403.
15 Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25(2):83–8.
16 Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324–33.
17 Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 2014;17(2):33–7.
18 Burns AM, Erickson DH, Brenner CA. Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatr Serv. 2014;65(7):874–80.
19 Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148(1–3):117–21.
20 Pennington M, McCrone P. The Cost of Relapse in Schizophrenia. Pharmacoeconomics. 2017;35(9):921–36.
21 Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913–20.
22 Wang CY, et al. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry. 2010;167(6):676–85.
23 Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-a review of the past decade. Eur Psychiatry. 2012;27(1):9–18.
24 Bäuml J, Pitschel-Walz G, Berger H. Arbeitsbuch PsychoEdukation bei Schizophrenie (APES). Schattauer, Stuttgart, 2010.
25 Documed. compendium.ch. Documed AG, Basel, 2015.
26 Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686–93.
27 Vollversion der Behandlungsempfehlungen der Schweizerischen Gesellschaft für Psychiatrie und Psychotherapie (SGPP) zur Schizophrenie. Abrufbar unter:
https://www.psychiatrie.ch/sgpp/fachleute-und-kommissionen/behandlungsempfehlungen/.